News & Updates

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021 by

The high-affinity, humanized, anti-interleukin-23-p19 monoclonal antibody tildrakizumab showed durable efficacy and safety for the treatment of chronic plaque psoriasis, according to the week 256 findings of the reSURFACE 1 trial.

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

27 May 2021

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

25 May 2021 by

Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F, was superior to adalimumab in reducing the severity of plaque psoriasis, according to results of a phase III trial presented at AAD 2021.

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

25 May 2021

Psoriasis tied to highest liver disease risk relative to PsA, RA

25 May 2021

In patients receiving methotrexate (MTX), psoriasis, psoriatic arthritis (PsA), and rheumatoid arthritis (RA) contribute to the risk of liver disease distinctively, independent of other major risk factors, reveals a recent study. Incidence of liver disease is highest among those with psoriasis.

Psoriasis tied to highest liver disease risk relative to PsA, RA

25 May 2021

Baricitinib BREEZEs through in atopic dermatitis

25 May 2021 by

In adults with moderate-to-severe atopic dermatitis (AD), use of the oral, selective Janus kinase 1/2 inhibitor baricitinib* led to significant improvements in quality of life (QoL) parameters in AD, accordingly to subgroup analyses results of the BREEZE-AD5 trial.

Baricitinib BREEZEs through in atopic dermatitis

25 May 2021

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

Children treated with BRAF and MEK inhibitors are prone to cutaneous reactions, many of which result in alterations or interruptions in oncologic therapy, reports a study.

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

24 May 2021

Skin cleansers boost healing of incontinence‐associated dermatitis

22 May 2021 by

Using specialized skin cleansers and body wipes in combination with a skin protectant can keep a lid on skin deterioration and promote incontinence‐associated dermatitis (IAD) healing, according to a study.

Skin cleansers boost healing of incontinence‐associated dermatitis

22 May 2021

Teledermatology effective in diagnosis, management of inpatient disease

21 May 2021 by

Teleconsultation appears to perform well for dermatologic disease management in the inpatient setting and results in highly concordant diagnostic, evaluation, and management decisions when carried out by experienced dermatologists, a study has found.

Teledermatology effective in diagnosis, management of inpatient disease

21 May 2021

Dupilumab an alternative for children with severe AD

19 May 2021 by

The addition of the monoclonal antibody dupilumab to a standard topical corticosteroid (TCS) regimen led to significant improvements in scoring AD (SCORAD*) and its components, as well as EASI** scores, in children with severe atopic dermatitis (AD), according to data from the phase III LIBERTY AD PEDS trial presented at PAS 2021.

Dupilumab an alternative for children with severe AD

19 May 2021

Secukinumab shows sustained improvement in paediatric psoriasis

16 May 2021 by

Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.

Secukinumab shows sustained improvement in paediatric psoriasis

16 May 2021

Severe atopic eczema ups mortality risk in adults

15 May 2021

Very severe and predominantly active atopic eczema seems to increase mortality risk among adults, a recent study has found.

Severe atopic eczema ups mortality risk in adults

15 May 2021

News & Updates

Filter by Specialty:

Specialty:

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

Extension study reflects durable efficacy, safety of tildrakizumab for plaque psoriasis

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

Bimekizumab tops adalimumab in moderate-to-severe plaque psoriasis

Psoriasis tied to highest liver disease risk relative to PsA, RA

Psoriasis tied to highest liver disease risk relative to PsA, RA

Baricitinib BREEZEs through in atopic dermatitis

Baricitinib BREEZEs through in atopic dermatitis

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

Cutaneous reactions caused by BRAF, MEK inhibitors alter oncologic therapy in children

Skin cleansers boost healing of incontinence‐associated dermatitis

Skin cleansers boost healing of incontinence‐associated dermatitis

Teledermatology effective in diagnosis, management of inpatient disease

Teledermatology effective in diagnosis, management of inpatient disease

Dupilumab an alternative for children with severe AD

Dupilumab an alternative for children with severe AD

Secukinumab shows sustained improvement in paediatric psoriasis

Secukinumab shows sustained improvement in paediatric psoriasis

Severe atopic eczema ups mortality risk in adults

Severe atopic eczema ups mortality risk in adults